We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK: Senate Report Ignores Data About Avandia’s Cardio Risks
GSK: Senate Report Ignores Data About Avandia’s Cardio Risks
March 3, 2010
GlaxoSmithKline (GSK) is challenging a recent Senate Finance Committee report associating cardiovascular risks with GSK’s diabetes drug Avandia, saying the report contains factual errors and omissions.